NEWS

Press Releases

Media Coverage

Additional Partnerships

For all media inquiries, please contact media@tempus.com

01/13/2022
Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations

Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline...
08/04/2021
- Genomic Sequencing
- Germline
Tempus Announces New Genomic Sequencing Lab in Research Triangle Park in Durham, NC

Tempus, a leader in artificial intelligence and precision medicine, today announced its new, state-of-the-art genomic sequencing lab in Durham’s Research Triangle Park (RTP). The 52,000-square foot space marks Tempus’ third laboratory, joining the company’s existing CAP-accredited/CLIA-certified labs in Atlanta and its Chicago headquarters. RTP’s proxi...
06/01/2021
Tempus Announces Eleven Abstracts Accepted for Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 - 8. “These high impact ASCO presentations from Tempus collaborators and investigators illustrate the power of over 35 pe...
02/09/2021
Tempus Launches Hereditary Cancer Germline Assay, xG

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its new germline sequencing assay, xG, a 52-gene panel that specifically identifies genetic variants associated with hereditary cancer syndromes and inherited risk of cancer. Tempus xG, which is now available to order, is performed by GeneDx, I...
04/21/2020
- Germline
- Neuro/Psych
Tempus Announces Prospective Psychiatric Study

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced its new prospective, pharmacogenomics study in psychiatry. The observational study aims to demonstrate the need for more transparent and reliable access to public data specific to a patient’s pharmacogenetic...
09/30/2019
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a study in Nature Biotechnology, one of the industry’s leading peer-reviewed, scientific journals, surrounding its xT platform. The study, which focuses on 500 patient samples across diverse tumor types ana...
07/20/2017
Tempus xO Assay Validation

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and integrating molecular and clinical data, today announced its Tempus xO assay has been validated with clinically actionable variance. The Tempus xO assay combines a 1,711 gene somatic and germline DNA sequencing panel with RNA-sequencing. It...
10/11/2016
- Clinical Trials
- Germline
Tempus And University of Michigan announce partnership for cancer patients

Tempus, a health-tech company focused on personalizing cancer care, and the University of Michigan Comprehensive Cancer Center have partnered to bring MI-ONCOSEQ to patients and health care providers across the country who are seeking the high quality data and analyses necessary to personalize treatment for their patients.The M...